Apple
AAPL
Taylor Morrison Home
TMHC
D.R. Horton
DHI
Petroleo Brasileiro SA Petrobras
PBR
Vale SA
VALE
US Stock MarketDetailed Quotes
ARQT Arcutis Biotherapeutics
- 16.090
- -0.380-2.31%
Close Mar 27 16:00 ET
- 16.170
- +0.080+0.50%
Pre 08:31 ET
1.91BMarket Cap-13.87P/E (TTM)
16.620High15.960Low1.46MVolume16.390Open16.470Pre Close23.62MTurnover1.71%Turnover RatioLossP/E (Static)118.64MShares17.75052wk High12.12P/B1.37BFloat Cap6.99052wk Low--Dividend TTM85.25MShs Float40.880Historical High--Div YieldTTM4.01%Amplitude1.760Historical Low16.163Avg Price1Lot Size
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Arcutis Biotherapeutics Stock Forum
Arcutis Biotherapeutics
(ARQT.US)
Tonix Pharmaceuticals
(TNXP.US)
As of March 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price act...
Could This New Eczema Cream Bring Relief to Millions of Toddlers? FDA Now Reviewing
📊⚡️📊
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
Positive
▪️Q4 2024 revenue grew 366% YoY to $63 million
▪️Full-year 2024 revenue increased 449% YoY to $160 million
▪️Strong quarter-over-quarter growth of 41% in Q4 2024
▪️Robust liquidity position of $329 million including available debt
▪️Option to re-draw $100 million deb...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...
Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Rubric Capital Management LP(9.38%),David Rosen(9.38%)
Long-term! 😜
1 MINUTE AGO, 8:20 AM EDT
VIA GLOBENEWSWIRE
No comment yet